index - Epidemiology in dermatology and evaluation of therapeutics

DOCUMENTS

98

 

NOTICES

156

 

 

MOTS CLES

Pregnancy Management Aging Auto-Diagnostic Biologics Pharmacovigilance Anticancer drugs Network meta-analysis Amyloidosis Albinism Psoriasis Access to care Spondylitis Graft-versus-host disease Adolescent Antibiotics Immunotherapy Méta-Analyse Alitretinoin Atrial fibrillation Cardio-oncology Autoimmunity Anti-TNF Azathioprine Arthritis Pharmacoepidemiology Prostate cancer Ustekinumab Angiotensin receptor blockers Primary adrenal insufficiency Auto-immune hepatitis Bacterial rhinosinusitis ArtThese Placebo ASDAS Abus d'antibiotiques Adalimumab Biologic drug Autoimmune diseases Biosimilar Pharmaceuticals Immune checkpoint inhibitors Biomédicaments Drug survival Arrhythmia Biologic therapy Biological therapy Apre-milast Systematic review Etanercept Bacterial Glucocorticoids Apremilast Quality of life Alcohol Treatment Biomarkers Burden Anti-HCV Direct Acting Antivirals DAA Cancer Antibiotic misuse Antimicrobiens Cardiotoxicity Biological Therapy Epidemiology Beta-lactam antibiotics Anxiety Stability Infliximab Immune-related adverse events Anti-Bacterial Agents COVID-19 Vigibase® Adverse side effects Ankylosing spondylitis Angiotensin-converting enzyme inhibitors Spondyloarthritis Atopic dermatitis Antimicrobials Antimicrobial resistance Addiction Intensive care Sipuleucel-T Meta-Analysis Sacroiliitis Drug reaction Ankylosing Endocrine toxicity Biologic Cardiomyopathy Dermatology BTK protein Axial spondyloarthritis Ethics Psoriatic arthritis Anxiété Accelerometer Acute Myeloid Leukaemia AML Pharmaco-Épidémiologie Antimicrobial Stewardship Antibiotic resistance

 

 

 

Epidemiology in Dermatology and Evaluation of therapeutics , EA 7379

Adresse

Université Paris-Est Créteil Val de Marne (UPEC)

Campus Centre de Créteil
61 Avenue du Général de Gaulle
94010 Créteil Cedex

Courriel

emilie.sbidian@aphp.fr

Site Internet

 

Rattachement(s)

UFR de Santé

Direction

Émilie SBIDIAN

 

Axe(s) de recherche

 


[legende-image]65[/legende-image] Axe 1 : Comment mieux gérer les patients ayant développé des réactins graves aux médicaments, notamment en leur indiquant comment utiliser correctement les agents


[legende-image]65[/legende-image] Axe 2 : Rechercher les facteurs associés aux effets indesirables et à l'efficacité du médicament

 
 

COLLABORATIONS